Sprint Bioscience

24/04/2026

Sprint Biosciences CEO Johan Emilsson presented the company and its operations at an investor event hosted by https://www.aktieinfo.net/ Aktieinfo John Stihøj in Aarhus, Denmark, on April 22. We appreciated the opportunity to share insights into our business and to meet members of the investment community, and it was very encouraging to see a strong turnout and high level of engagement from the audience in person. See the presentation and the subsequent Q&A session here 🎞️ https://sprintbioscience.com/en/movie/sprint-bioscience-presenterar-pa-aktieinfo-net-investerartraff/

22/04/2026

Today at AACR 2026 by American Association for Cancer Research (AACR) we are presenting data from our DCPS program, supporting DCPS inhibition as a promising therapeutic strategy for patients with acute myeloid leukemia (AML). The findings go beyond efficacy, providing deeper biological insight into DCPS and highlighting its potential role in improving patient stratification. Sprint Bioscience is represented by CSO Martin Andersson and Associate Principal Scientist Madhurendra Singh. Come by and discuss the data with us!
📍 Biomarkers Predictive of Therapeutic Benefit 6
🗓️ Wednesday, April 22 | Poster Section 41, Board 18

21/04/2026

At a time when the global cancer burden continues to rise, scientific progress cannot afford silos, slowdowns, or hesitation. Breakthroughs happen when knowledge is shared, challenged, and accelerated. That is why Sprint Bioscience is proud to participate in the American Association for Cancer Research (AACR) Annual Meeting 2026, the world’s largest and most influential cancer research convening.

Ahead of the main meeting, our CSO and co‑founder Martin Andersson participated in the AACR Oncology Industry Partnering Event (April 16–17), engaging with leaders across biotech and pharma. These discussions are where science meets strategy and where discoveries begin their journey toward patients.

The Annual Meeting (April 17–22) is currently underway, where Madhurendra Singh will present new preclinical data from our DCPS program. The poster highlights findings supporting DCPS inhibition as a potential therapeutic strategy for patients with acute myeloid leukemia (AML). Beyond efficacy, the data deepens the biological understanding of DCPS and underscore its potential to improve patient stratification.
🔔Wednesday, April 22 Biomarkers Predictive of Therapeutic Benefit 6 📍Location: Poster Section 41 Poster Board Number: 18

Events like AACR matter because no single lab, company, or discipline can solve cancer alone. In times of scientific complexity, geopolitical uncertainty, and mounting healthcare pressure, platforms for exchange and collaboration are not optional, they are essential.
Cancer does not wait. Neither can drug discovery.

15/04/2026

Sprint Bioscience’s Annual Report for 2025 is now available. Download your copy or read it online (in Swedish):

▪️https://sprintbioscience.com/sv/pressmeddelande/?slug=sprint-bioscience-arsredovisning
▪️Subscribe to receive future press releases and stay updated:

https://sprintbioscience.com/sv/investerare/

31/03/2026

Just in case you missed our post last week we can now proudly share it all over again because the feature in Life Science Sweden is now available in English!

▪️ Read the full article here (in English!): https://www.lifesciencesweden.se/article/view/1218102/sprint_bioscience_builds_the_molecules_that_will_become_new_medicines

The feature showcases our continued commitment to advancing innovative drug discovery and contributing to the development of future therapies. And once again, yes even this week, we’re grateful for the visibility and inspired to keep pushing the boundaries of what’s possible. 📸 Screenshot used with permission ©Life Science Sweden

27/03/2026

Sprint Bioscience are pleased to announce that groundbreaking findings from our DCPS program have once again been published, this time in the scientific journal Discover Oncology from Springer Nature. https://link.springer.com/article/10.1007/s12672-026-04880-x

“The new findings provide strong support for DCPS inhibition and clearly show how FHIT and IDH2 can be used to identify the patients who stand to benefit the most from DCPS-targeted treatment,” said Martin Andersson, Chief Scientific Officer at Sprint Bioscience.

The article is a collaboration between Sprint Bioscience AB (publ), NeoTargets AB, and research groups led by Dr. Julian Walfridsson and Magnus Tobiasson at Karolinska Institutet. It has been partially funded by the Swedish Foundation for Strategic Research Stiftelsen för strategisk forskning, SSF through an industrial PhD fellowship.

Read the full press release here▪️https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-publishes-new-research-findings-that-strengthen-the-potential-of-dcps-inhibitors-in-aml

24/03/2026

We’re excited to share that our company is featured in Science Sweden!
Being highlighted by one of the leading media in the Nordic life science community is a proud moment for our team. The article showcases our continued commitment to advancing innovative drug discovery and contributing to the development of future therapies. A few key takeaways from the feature:

🟣 Recognition of our scientific approach and dedication to early‑stage drug development.

🟣 Spotlight on how our technology and methods can contribute to new treatment opportunities for cancer.

🟣 Acknowledgment of our team’s hard work and forward‑looking mindset.

▪️ Read the full article here (for now only available in Swedish): https://www.lifesciencesweden.se/article/view/1218102/sprint_bioscience_bygger_molekylerna_som_ska_bli_nya_lakemedel

We’re grateful for the visibility and inspired to keep pushing the boundaries of what’s possible.

20/03/2026

We are proud to share that our teams continue to deliver important scientific progress across our portfolio. Following the recently presented in vivo data from our glioblastoma program, we are now preparing to unveil new preclinical results in acute myeloid leukaemia (AML) at the AACR Annual Meeting in April.
To discuss these advancements, our Chief Scientific Officer Martin Andersson joined the BioStock - Connecting Innovation & Capital studio for an interview.
Watch the full conversation: https://biostock.se/en/2026/03/positiva-data-och-kommande-presentationer-sprint-biosciences-cso-berattar-mer/

Watch the whole interview with CSO Martin Andersson here.

18/03/2026

Sprint Bioscience presents new preclinical data from the company’s DCPS research program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. 🟣https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-presents-new-preclinical-data-on-dcps-at-the-aacr-annual-meeting-2026

The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience.

The AACR Annual Meeting is one of the world’s most prominent scientific conferences in cancer research, bringing together leading researchers, clinicians, and drug developers. More information about the conference is available on AACR’s official website: https://www.aacr.org/meeting/aacr-annual-meeting-2026/


▪️ Subscribe for future press releases https://sprintbioscience.com/en/subscribe/

17/03/2026

Sprint Bioscience today announces positive results from a pre-clinical proof-of-concept (POC) study performed within our VRK1 program. The results show that VRK1 inhibition selectively kills glioblastoma cells with low VRK2 levels, while cells with normal VRK2 levels are not affected. This confirms the tumor‑specific mechanism of the program and demonstrates that VRK1 is a relevant target for the treatment of VRK2‑low glioblastoma.

“We are thrilled to report a positive outcome from this POC study. These results provide pharmacological validation of VRK1 as a relevant target in glioblastoma. To our knowledge, this is the first demonstration of anti-tumor effects from selective VRK1 inhibition in vivo. We look forward to presenting these results at upcoming partnering conferences,” said Martin Andersson, Chief Scientific Officer at Sprint Bioscience.
🟣https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-reports-positive-results-from-the-vrk1-program

11/03/2026

At Sprint Bioscience, we are proud to attend, through our CEO Johan Emilsson, Cancerfonden’s 75th Anniversary Gala, an evening that honors the type of research that forms the foundation of tomorrow’s medicines. 💜

As a research‑driven company, our work is built in part on the fundamental research and discoveries that, among other things, are made possible by Cancerfonden. Since 1951, the foundation has contributed SEK 17 billion to Swedish cancer research. Thanks to long‑term commitments and the relentless efforts of scientists, seven out of ten people diagnosed with cancer survive today, compared with three out of ten when Cancerfonden was founded. These advances are the result of researchers who never give up, and without their tireless work, our company would not exist.

We are grateful for the invitation and for the opportunity to share the evening with those who push fundamental research forward, every single day.

16/01/2026

Do you breathe science?
Do you thrive in the lab?
Do you want to work in an efficient and multidisciplinary research environment?

We are now looking for someone who shares our passion for laboratory work in cell biology to become a part of our Tumor Biology and Therapeutics team. Apply today!🔗https://sprintbioscience.com/en/career/